行情

HZNP

HZNP

Horizon Therapeutics Plc
NASDAQ

实时行情|Nasdaq Last Sale

30.95
+0.19
+0.62%
交易中 15:08 04/08 EDT
开盘
31.00
昨收
30.76
最高
31.24
最低
30.10
成交量
120.51万
成交额
--
52周最高
39.10
52周最低
22.69
市值
58.85亿
市盈率(TTM)
15.24
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测HZNP价格均价为44.40,最高价位50.00,最低价为38.00。

EPS

HZNP 新闻

更多
  • Should You Buy These 3 Biotechs Now?
  • MotleyFool.com · 5天前
  • Horizon acquires Curzion Pharma for $45M
  • Seeking Alpha - Article · 6天前
  • Morgan Stanley Maintains Overweight on Horizon Therapeutics, Lowers Price Target to $39
  • Benzinga · 6天前
  • Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
  • Business Wire · 6天前

所属板块

制药
+3.06%
制药与医学研究
+3.08%

热门股票

代码
价格
涨跌幅

HZNP 简况

Horizon Therapeutics plc, formerly Horizon Pharma plc, is a rare disease biopharmaceutical company. The Company is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The Company markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
展开

微牛提供Horizon Therapeutics PLC(NASDAQ-HZNP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的HZNP股票新闻,以帮助您做出投资决策。